Cantor Fitzgerald Estimates ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.27) per share.

A number of other brokerages have also recently issued reports on ESPR. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, December 12th. StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a report on Wednesday. They set a "neutral" rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $7.30.

Esperion Therapeutics Stock Up 0.5 %

Shares of Esperion Therapeutics stock traded up $0.01 on Thursday, hitting $2.17. The company's stock had a trading volume of 3,604,291 shares, compared to its average volume of 6,378,579. The company has a market capitalization of $427.57 million, a P/E ratio of -3.39 and a beta of 1.01. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The firm has a fifty day moving average price of $2.41 and a 200-day moving average price of $2.22.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently made changes to their positions in ESPR. Wasatch Advisors LP lifted its position in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. Marshall Wace LLP increased its stake in shares of Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after acquiring an additional 2,087,635 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company's stock worth $1,271,000 after acquiring an additional 555,382 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics in the third quarter worth approximately $606,000. Finally, Inspire Investing LLC acquired a new stake in shares of Esperion Therapeutics in the second quarter worth approximately $758,000. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.